Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

Abstract: The invention provides methods or compositions for treating cancer using a superantigen conjugate in combination with a B-cell depleting agent, e.g., an anti-CD20 antibody.

Abstract: The invention provides methods or compositions for treating cancer using an immune cell, e.g, a T-cell, e.g., a CAR T-cell, optionally in combination with a superantigen conjugate. The invention also provides methods for making immune cells, e.g, T-cells, e.g, CAR T-cells, for use in the treatment of cancer.

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

Abstract: The invention provides methods or compositions for treating cancer using a superantigen conjugate optionally in combination with a PD-1-based inhibitor.

Abstract: Provided is a method for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

Abstract: Provided is a method for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

Abstract: Provided are pharmaceutical compositions including macrophage activating factor derived from Gc protein (GcMAF) for use in treating benign or precancerous papillomas. Further provided are pharmaceutical compositions including GcMAF for use in treating recurrent respiratory papillomatosis (RRP).

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

Abstract: A pharmaceutical composition that includes stable Gc macrophage activating factor (GcMAF) or a biologically active variant or fragment thereof and at least one pharmaceutically acceptable excipient selected from the group consisting of a surfactant and a synthetic water-soluble polymer having surface activity. These compositions are storage stable and are used for treating a disease or disorder associated with macrophage activation.

Abstract: The present invention is of a kit and electricity generating device for delivery of an encapsulated composition or mixture of compositions, including an electricity generating device and at least one composition in an encapsulated carrier vehicle which is contacted or applied to the electricity generating device. In some embodiments the device includes a means for maintaining stability of the encapsulated composition prior to bio-membrane penetration. The present invention also provides methods of use thereof. Furthermore, the present invention provides a device and method for delivering a fixed ratio of compounds from a mixture to a bio-membrane comprising the step of electro-transporting an encapsulated mixture of compounds. Still further, the present invention is of a device and method for delivering each compound of a mixture of compounds to the same penetration depth.

Abstract: A method, device and kit for body decoration. Embodiments of the kit include an ink suitable for body decoration, means for applying the ink to a desired body area, and an electrically powered patch detachably coupled to the application means to promote penetration of the ink into the body area. Embodiments of the device include a fully integrated patch device. The patch device integrates the elements of a kit (i.e., a color formulation, a means for applying, and a patch) into a stand-alone patch. Embodiments of the method include contacting the desired body area with a means for applying, applying ink through the means for applying, and promoting penetration of the ink into the body area with the patch by applying electric current to the ink application. Exemplary applications include temporary and permanent tattooing, applying semi-permanent cosmetics, animal tattooing, and administering therapeutic treatments.

Abstract: The invention provides diastereomeric peptides with a net positive charge greater than +1, and cyclic analogues thereof, having at least 15 amino acid residues, wherein said residues are selected from: (i) leucine and lysine;, (ii) leucine, lysine and arginine; (iii) glycine, serine, spargine, threonine, or glutamine optionally present at the N-terminus; (iv) and/or lysine, arginine, glycine, or serine optionally present at the C-terminus. The diastereomeric peptides are suitable for treatment of cancer and for treatment, particularly topical treatment, of infections caused by pathogenic organisms such as bacteria and fungi. In addition, they may be used for controlling, mycoplasma infection in cell cultures and for food preservation as food supplements and as alternative to antibiotics for animal nutrition.